Antitumor and antimetastatic effect of warfarin and heparins

Biomedicine and Pharmacotherapy

Volumn 58, Issue 4, 2004, Pages 213-219

  Bobek, Vladimir ^a   Kovařík, Josef ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer; Heparin; Metastasis; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER SURVIVAL; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; EVALUATION; HUMAN; IMMUNE SYSTEM; LIVER METASTASIS; LUNG SMALL CELL CANCER; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TUMOR GROWTH;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEPARIN; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; WARFARIN;

EID: 2942563927     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.11.007     Document Type: Review

References (96)

1. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 91:1999;22-26
2. Smorenburg S.N., Van Noorden C.J.F. The complex effects on heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 53:2001;93-105
3. Li H.L., Ye K.H., Zhang H.W., Luo Y.R., Ren X.D., Xiong A.H., et al. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res. 11:2001;311-315
4. Meyer T., Hart I.R. Mechanisms of tumour metastasis. Eur Cancer. 34:1998;214-221
5. Zacharski L.R., Ornstein D.R. Heparin and cancer. Thromb Haemost. 80:1998;10-23
6. Elias E.G., Shukla S.K., Mink I.B. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer. 36:1975;129-136
7. Milas L., Hunter A., Basic I. Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits. Clin Exp Metastasis. 3:1985;247-255
8. Maat B., Hilgard P. Anticoagulants and experimental metastases - evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol. 101:1981;275-283
9. Wood S, Holyoke ED, Yardley JH. Mechanisms of metastatic production by blood-borne cancer cells. Can Cancer Conf 4:167-223;161.
10. Lee J.K., Choi B., Sobel R.A., Chioca E.A., Martuza R.L. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg. 73:1990;429-435
11. Lee A.E., Rogers L.A., Jeffery R.E., Longcroft J.M. Comparison of metastatic cell lines derived from a murine mammary tumor and reduction of metastasis by heparin. Clin Exp Metastasis. 6:1988;463-471
12. Drago J.R., Weed P., Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma. Anticancer Res. 4:1984;171-172
13. Tiozzo R., Cingi M.R., Pietrangelo A., Albertazz L., Calandra S., Milani M.R. Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various types cells. Arzneim-Forsch. 39:1989;15-20
14. Au Y.P., Kenagy R.D., Clowes M.M., Lowes A.W. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 23:(Suppl 1):1993;177-182
15. Bennet M.R., Evan G.I., Newby A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin and cyclic nucleotide analogues and induces apoptosis. Circ Res. 74:1994;525-536
16. Lebeau B., Chastang C., Brechot J.M., Capron F., Dautzenberg B., Delasements C., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 74:1994;38-45
17. Aramaki M., Katsunori K., Atsushi S., Tsuyoshi O., Koichiro T., Yuu T., et al. Potential role of heparin in prevention of liver metastasis from colon cancer. Hepato Gastroenterol. 46:1999;3241-3243
18. Vlodavsky I., Mohsen M., Lider O., Svahn C.M., Ekre H.O., Vigoda M., et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis. 14:1994-95;290-302
19. Sciumbata T., Caretto P., Pirovano P., Pozzi P., Cremonesi P., Galimberti G., et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis. 16:1996;132-143
20. Folkman J., Langer R., Linhart R.J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 221:1983;719-725
21. Lapierre F., Holme K., Lam L., Tressler R.J., Storm A., Wee J., et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 6:1996;355-366
22. McCulloch P., George W.D. Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br J Cancer. 59:1989;179-183
23. McCulloch P., George W.D. Warfarin inhibition of metastasis: the role of anticoagulation. Br J Surg. 74:1987;879-883
24. Folkmann J. Angoiogenesis and angiogenesis inhibition: an overview. EXS. 79:1997;1-8
25. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis. 23:(Suppl 1):1993;141-149
26. Norrby K., Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp. 16:1996;8-15
27. Jayson G., Gallagher J.T. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 ells. Br J Cancer. 75:1997;9-16
28. Soker S., Goldstaub D., Svahn C.M., Vlodavski I., Levi B.Z., Neufeld G. Variation in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF 165 to its receptors. Biochem Biophys Res Commun. 203:1994;1339-1347
29. Lepri A., Benelli U., Bernardini A., Bianchi F., Lupetti M., Danesi R., et al. J Ocul Pharmacol. 10:1994;273-280
30. Constantini V., Zacharski L.R. The role of fibrin in tumor metastasis. Cancer Metastasis Rev. 11:1992;283-290
31. Dvorak H.F., Harvey V.S., Estrella P., Brown L.F., Mdonagh J., Dvorak A.M. Fibrin containing gels induce angiogenesis. Implication for tumor stroma generation and wound healing. Lab Invest. 57:1987;673-686
32. Collen A., Koolwijk P., Kroon M.E., van Hinsbergh V.W.M. The influence of fibrin structure on the formation and maintenance of capillary-like tubules. Angiogenesis. 2:1998;153-165
33. Parise P., Morini M., Agnelli G., Ascani A., Nenci G.G. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induce lysis. Blood Coagul Fibrinolysis. 4:1993;721-727
34. Collen A., Smorenburg S.M., Peters E., Lupu F., Koolwijk P., Van Noorden C.J.F., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 60:2000;6196-6200
35. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., Broze G.J. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 78:1991;387-393
36. Pepe G., Giusti B., Attanasio M., Gori A.M., Omeglio P., Martini F., et al. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemostasis. 23:1997;135-141
37. Ruf W., Mueller B. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol. 3:1996;379-384
38. Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 19:2001;1207-11205
39. Kakkar A., Chinswangwatanakul V., Lemonide N., Tebbut S., Williamson R. Role of tissue factor expression on tumor cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg. 86:1999;890-894
40. Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., et al. Tissue factors controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 94:1994;1320-1327
41. Bromberg M.E., Sundaram R., Homer R.J., Garen A., Koenigsberg W.H. Role of tissue factor in metastasis: functions of the cytoplasmatic and extracellular domains if the molecule. Thromb Haemostasis. 82:1999;88-92
42. Abe K., Shoji M., Chen J., Bierhaus A., Danave I., Micko C., et al. Regulation of vascular endothelial growth factor production and angiogenesis by cytoplasmatic tail of tissue factor. Proc Natl Acad Sci USA. 96:1999;8663-8668
43. Mousa S.A. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost. 28:2002;45-52
44. Hilgard P. The use of oral anticoagulant in tumor therapy. Donati M., Davidson J., Garettini S. Malignancy and the hemostatic system. 1981;103 Raven Press, New York
45. Maat B. Selective macrophage inhibition abolishes warfarin-induced reduction of metastasis. Br J Cancer. 41:1980;313-316
46. Gorelik E., Wiltrout R.H., Okumura K., Habu S., Herberman R.B. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer. 30:1982;107-112
47. Gorelik E., Bere W.W., Heberman B. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer. 33:1984;87-94
48. Gorelik E. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Cancer Res. 47:1987;809-815
49. Ostensen M.E., Thiele D.L., Lipsky P.E. Tumor necrosis factor enhances cytolytic activity of human natural killer cells. J Immunol. 138:1987;4185-4195
50. Ortaldo J.R. Regulation of natural killer activity. Cancer Metastasis Rev. 1987;637-651
51. Sylvester D.M., Liu S.-Y., Meadows G.G. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immunopharmacol Immunotoxicol. 12:1990;161-180
52. Itoh K., Nakao A., Kishimoto W., Takagi H. Heparin effects on superoxide production by neutrophils. Eur Surg Res. 27:1995;184-188
53. Leculier C., Coupire A., Adeleine P., Leitienna P., Franina A., Richard M. The effects of high molecular weight and low molecular weight heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb Res. 69:1993;519-531
54. Handa K., Nudelman E.D., Stroud M.R., Shiozawa T., Hakomori S. Selectin GMP-140 (D62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding. Biochem Biophys Res Commun. 181:1991;1223-1230
55. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 82:1993;3253-3258
56. Koenig A., Norgard-Sumnicht K., Linhardt R., Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractioned and low molecular weight heparins as therapeutic agents. J Clin Invest. 101:1998;877-889
57. Atanahopoulos C.T., Iliopoulos D.C., Gagos S., Agapitos M.V., Karayannacos P.E., Roboli S.K., et al. In vitro effects of heparin on SW480 tumor cell matrix interaction. Anticancer Res. 15:1995;1411-1416
58. Saiki I., Murata J., Nakajima M., Tokura S., Azuma I. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res. 50:1990;3631-3637
59. McCarthy J.B., Skubitz A.P., Qi Z., Yi X.Y., Mickelson D.J., Klein D.J., et al. RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities. J Cell Biol. 110:1990;777-787
60. Liang O.D., Rosenblatt S., Chhatwall G.S., Preissner K.T. Identification of novel heparin-binding domains of vibronectin. FEBS Lett. 407:1997;169-172
61. Othaka K., Watanabe S., Iwazaki R., Hirose M., Sato N. Role of extracellular matrix on colonic cancer cell migration and proliferation. Biochem Biophys Res Commun. 220:1996;346-352
62. Nakajima M., Irimura T., Nicolson G.L. Heparanases and tumor metastasis. J Cell Biochem. 36:1988;157-167
63. Eccles S.A. Heparanase: breaking down barriers in tumors. Nat Med. 5:1999;735-736
64. Lersch C., Gericke D., Classen M. Efficacy of low-molecular-weight heparin and unfractioned heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. Urol Int. 56:1996;230-233
65. Bobek V., Moubelik M., Kovařík J., Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma. 50:2003;148-151
66. A, and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J Gastroenterol. 36:2001;166-172
67. Srinivas U., Pahlsson P., Lundblad A. E-selectin: sialyl Lewis, a dependent adhesion of colon cancer cells, is inhibited differently by antibodies against E-selectin ligands. Scand J Immunol. 44:1996;197-203
68. x is recognised by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 266:1991;14869-14872
69. Satoh H., Ishikawa H., Kamma H., Yamashita Y.T., Takahashi H., Ohtsuka M., et al. Serum sialyl Lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res. 3:1997;495-499
70. X antigen defined by Mab-3 is an independent prognostic marker in colorectal carcinoma patients. Int J Cancer. 88:2000;281-286
71. Yamaguchi A., Ding K., Maehara M., Goi T., Nakagawara G. Expression of nm23-H1 gene and sialyl Lewis X antigen in breast cancer. Oncology. 55:1998;357-362
72. Dennis J.W., Laferte S. Tumor cell surface carbohydrate and the metastatic phenotype. Cancer Metastasis Rev. 5:1987;185-204
73. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56:1996;5309-5318
74. Kim Y.J., Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugate J. 14:1997;569-576
75. Takada A., Ohmori K., Yoneda T., Tsuyoka K., Hasegava A., Kiso M., et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 53:1993;354-361
76. Varki A. Selectin ligands. Proc Natl Acad Sci USA. 91:1994;7390-7397
77. Kansas G.S. Selectins and their ligands: current concepts and controversies. Blood. 88:1996;3259-3287
78. Varki A., Varki N.M. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res. 34:2001;711-717
79. Koenig A., Norgard-Sumnicht K.E., Linhardt R., Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 101:1998;877-889
80. Nieswandt B., Hafner M., Echtendacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59:1999;1295-1300
81. Tang D.G., Honn K.V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 14:1994;109-122
82. Amirkhosravi A., Mousa S.A., Amaya M., Francis J.L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost. 1:2003;1972-1976
83. Amirkhosravi A., Amaya M., Siddiqui F., Biggerstaff J.P., Meyer T.V., Francis J.L. Blockade of GpIIb/IIIa inhibits release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets. 10:1999;285-292
84. Mohle R., Green D., Moore M.A.S., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 94:1997;663-668
85. Maloney J.P., Sillimann C.C., Ambruso D.R., Wang J., Tuder R.M., Voekel N.F. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 275:1995;H1054-H1061
86. Verheul H.M.W., Jorna A.S., Hoekman K., Broxterman H.J., Gebbink M.F., Pinedo H.M. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 96:2000;4216-4221
87. Trikha M., Zhou Z., Timar J., Raso E., Kennel M., Emmell E., Nakada M.T. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62:2002;2824-2833
88. Prandoni P., Piccioli A., Girolami A. Cancer and venous thromboembolism: an overview. Haematologica. 84:1999;437-445
89. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell C.J., Forcier R.J., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer. 53:1984;2046-2052
90. Prandoni P., Lensing A.W.A., Buller H.R., Carta M., Cogo A., Vigo M., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 339:1992;441-445
91. Hull R.D., Raskob G.L., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G., et al. Subcutaneous low molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. New Engl J Med. 326:1992;975-982
92. Prandoni P., Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Front Biosci. 2:1997;e12-20
93. Kakkar A., Hedges A.R., Williamson R.C.N., Kakkar V.V. Preoperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol. 6:1995;885-888
94. Kohanna F.H., Sweeney J., Sheila H., Zaharski L.R., Salzman E.W. Effect of preoperative low-dose heparin administration on the course of colon cancer. Surgery. 93:1983;433-438
95. Wojtukiewicz M.Z. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost. 89:2003;405-407
96. von Tempelhoff G.F., Harenberg J., Niemann F., Hommel G., Kirkpatrick C.J., Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 16:2000;815-824